

## **PEDIATRIC OBESITY AND VITAMIN D DEFICIENCY: A CONCEPT AND UNDERSTANDING**

**ADILO S. BAHATHIQ**

Vice-Dean, Public Health and Health Informatics, Associate Professor in Reproductive Endocrinology,  
Department of Physiology, College of Medicine, UMM-ALQURA University, Makkah, Saudi Arabia

### **ABSTRACT**

Pediatrics obesity is a major community health issues globally now days. The commonness of Pediatrics obesity and vitamin D deficiency has increased over in several decades. It is caused by imbalance between calories intake and calories utilized in body. One or more factors cause obesity in children that is Physical, psychological, and social health problems are caused due to childhood obesity. Effective active strategies can be used to prevent and control obesity in children which is more effective. The purpose of this paper is to address various factors influencing childhood obesity and vitamin D deficiency. It is also addressing the sources of Vitamin D, classification, Risk factors, the role of vitamin D on adipose tissue, the genetic role in vitamin D and obesity, the role of inflammation on obesity and Vitamin D status in Middle East, etc.

**KEYWORDS:** Child Obesity, Pediatric Obesity, Vitamin D Deficiency

### **INTRODUCTION SYNTHESIS OF VITAMIN D**

Vitamin D or sunshine vitamin, its main and major source is obtained from the sun exposure and minor source is obtained from diet (dairy products, oil fish, meat and eggs) [1-16].

It consumed few steps to be synthesized. In the skin, UV-B wavelengths in sunlight convert 7-dehydrocholesterol to cholecalciferol (vitamin D<sub>3</sub>), which has the ability to enter the circulation. In the liver, vitamin D<sub>3</sub> by the 1<sup>st</sup> hydroxylation step it become 25(OH)D. In the kidney, by the 2<sup>nd</sup> hydroxylation step it converted to 1,25(OH)<sub>2</sub>D<sub>3</sub> which is the bioactive form. Later on, this final active form has the ability to bind to VDRs and act through it [1-16]. VDRs are distributed throughout the body in the endocrine glands, endothelial cells, vascular smooth muscle cells, cardiomyocytes and hemolymphopoietic cells[1,17,18].


### **CLASSIFICATION**

We can define vitamin D deficiency based on the following stratifications of 25(OH)D serum concentration[1,16,19,20,21]:

- Deficiency <50.0 nmol/L or <20.0 ng/mL
- Insufficiency = 50.0–74.9 nmol/L or 20.0–29.9 ng/mL
- Sufficiency ≥75.0 nmol/L or ≥30.0 ng/mL

We can define obesity based on the following stratifications of BMI:

- Underweight < 18.5
- Healthy = 18.5 to 24.9
- Overweight = 25 to 29.9
- Obese  $\geq 30$



**Figure: 1: Synthesis of Vitamin D**

## RISK FACTORS

Vitamin D deficiency is an independent risk factor for obesity in women [3-30]. In children it is associated with growth retardation and skeletal deformities. Moreover, new evidence provided an association between the levels of 25(OH)D and increasing age, obesity, reducing insulin sensitivity, hypertension, visceral obesity, hypertriglyceridemia, metabolic syndrome, immune function, respiratory diseases, infection, allergy, cancers, and cardiovascular diseases[3-32].

There is an indication signs of deviation in the endocrine system of vitamin D in obese subjects[3]:

- Increase in serum PTH.
- Increase in cAMP.
- Increase in renal tubular reabsorption of Ca.
- Increase circulating 1,25(OH)<sub>2</sub>D<sub>3</sub>.

- Decrease in serum level of 25(OH)D.
- Decrease in HDL.
- Increase in triglycerides and LDL.

The risk factors that link the deficiency of vitamin D with child obese subjects: decreased sunlight exposure, season (winter), limited outdoor activity, clothes that limit cutaneous vitamin D synthesis[4-57]. Moreover, low vitamin D levels in the mother during pregnancy play a role on her child's levels and lower birth weight but higher fat mass at 4 to 6 years old child, race (non-white), age of puberty, low milk consumption, female gender[12] and some mutations in VDR [13-74].

A study done by Thomas *et al.* provided an increase in PTH levels and a decrease in 25(OH)D levels in obese subjects. Since these changes normalized after weight loss so, these changes considered as a consequences rather than a risk factors[7-80].

#### **Low Concentration of Vitamin D in Obese Subjects Could be a Result of Deferent Mechanisms**

- FTO genotype variation could affect vitamin D levels and weight gain by decreasing the insulin effect in brain tissues, affecting appetite, food choice, and dietary intake from an early age[8-67].
- Direct relationship between circulating adiponectin and vitamin D levels. Inverse relationship between the circulating adiponectin and BMI[2-25]. Furthermore, patients with insulin resistance, type 2 diabetes and cardiovascular disease have lower concentration of adiponectin[2-25].
- The relationship between BMI and serum level of 25(OH)D is inverse, each unit increase in BMI being associated with 1.15% lower concentration of 25(OH)D[4-54].
- Body fats acts as a reservoir for vitamin D (lipid soluble vitamin), so increasing the content of body fats will increase its sequestration, leading to decrease its bioavailability[4-55].
- Some studies has been shown that 25(OH)D was stored 33% in fat and 20% in muscle. Based on these studies we can look at the muscles as another reservoir for vitamin D[4-56].
- In obese subjects and due to hepatic steatosis, the liver may lower the rate of 25(OH)D synthesis[4-58].
- High levels of leptin and IL6 (secreted by adipose tissue) may inhibit 1,25(OH)<sub>2</sub>D<sub>3</sub> synthesis[4-59].

#### **The Role of Vitamin D on Adipose Tissue**

Recently, new studies classified the adipose tissues as one of the major endocrine organs[4-60]. Divided into two types white and brown, each type has a different cell origin, structure and function[10]. The brown one are present in children only, it has an average life span of 10 years, so most of them disappears in adulthood[10]. At that time, they replaced by the white one[10]. Brown adipose tissues work as thermogenesis[4], while the white adipose tissues serve mainly as energy reserves, secrete hormones, mechanical protection and insulation to the body[10].

In response to high body weight there will be an increase in both fat mass and lean body mass (subtracting body fat weight from total body weight)[11]. That is how we explain the increase in fat mass; the adipose tissues are structurally plastic, so they have the ability to expand and become larger in size and number[4-61].

Some studies have shown that vitamin D has no direct effect on body weight, but it may have an effect on the fat mass and its distribution. This effect was seen only in subjects with 25(OH)D levels less than 50.0 nmol/L[4,62,63] .

### **The Genetic Role in Vitamin D and Obesity**


A study in Brazilian Amazon area, was found a significant relationship between an A allele of FTO rs9939609 and being obese during childhood. However, the study provided a pivotal role of vitamin D levels on altering the genotype effects on BMI. Deficient children presented larger increases in BMI for each A allele compared with normal children[8]. The variation at the FTO locus affects BMI in childhood by accelerating adiposity rebound and fat mass deposits[8-68], which may play a role in metabolic disease risk[8-69]. Taken together, we detect an important interaction between FTO and vitamin D levels in relation to childhood obesity, but the mechanisms of this interaction still remain unclear[8]. Furthermore, FTO gene is expressed in the human brain, and there is evidence of a relation between its risk allele and decreased cerebrocortical insulin sensitivity[8-70]. Some studies have mentioned a functional role for insulin in the regulation of energy homeostasis and body weight in the CNS[8-71]. Subsequently, a possible mechanism for the association between FTO genotype and vitamin D levels may involve insulin action at a central level[8,72,73].

### **The Role of Adiponectin on Vitamin D and Obesity**

Adiponectin is a protein produced by adipose tissues and secreted to adipocytes[2-29]. It is located within one of the susceptibility gene loci for obesity[2-24]. Clinical trials has been confirmed a difference in the plasma concentration of adiponectin in obese pediatric subjects between subjects with vitamin D deficiency and subjects with vitamin D sufficiency[2]. Adiponectin circulates in plasma in different forms: trimmers-(LMW), hexamers-(MMW) and hexamers-(HMW)[2-24]. HMW is identified as the most bioactive form[2-24]. The concentration of adiponectin in pediatric obese subjects with vitamin D deficiency was significantly lower than in pediatric obese subjects with vitamin D sufficiency[2]. Moreover, the greatest difference was observed in hexamers-HMW. It has been proved to have insulin sensitizing effects[2-25], regulates centrally food intake and body weight[2-26], cardioprotective[2-27], anti inflammatory and antioxidant properties[2-28], demonstrating that it has a clear clinical important role with respect to obesity and its comorbid conditions[2].

### **Matrix Metalloproteinases (MMPs) Enzymes**

MMPs enzymes play a role in tissue remodeling, migration of leucocytes, inflammation, infection and obesity. These enzymes are produced by different cell types, including lymphocytes, granulocytes, astrocytes, activated macrophages and adipose tissue[3].



Evidence and reports provided a remarkable increase in the levels of some enzymes (MMP-2, MMP-8 and MMP-9) in obese children[3,33,34,35]. Also, it has been shown a correlation between MMP-9 and BMI[3-36]. The study that provided an increase in MMP-8 levels, it also proved a decrease in TIMP-1 levels at the same time in obese subjects more than non-obese[3-37].

MMP-2 promoter haplotype play a role in the percentage of body fat in obese children[3-38]. Functional MMP-9 gene polymorphism is strongly associated with obesity[3-39], and MMP-9 genotypes and haplotypes affect MMP-9 levels in obese subjects[3-40].

VDR-KO mice play a role in some of these enzymes (MMP-2, MMP-9 and MMP-12) by up regulating their expression, reduce body weight, lower serum leptin concentrations and it also enhance the influx of inflammatory cells and phospho-acetylation of NF-κB in lungs[3-41]. Moreover, VDR TaqI polymorphism play a role in decreasing the production of TIMP-1[3-42]. 1,25(OH)<sub>2</sub>D<sub>3</sub> down regulated MMP-9 levels in keratinocytes, and may reduce the harmful effects of excessive TNF-α-induced proteolytic activity, which play a role in cutaneous inflammation[3-43]. It also inhibits both the basal levels and the staphylococcus-stimulated production of MMP-9 in human blood monocytes and alveolar macrophages[3-44]. In addition, some reports provided a beneficial role of vitamin D analog in reducing the expression of MMP-2, MMP-9, VEGF and PTH-related peptide in Lewis lung carcinoma cells[3-45]. Taken together, 1,25(OH)<sub>2</sub>D<sub>3</sub> may play an important role in obesity by down regulating MMPs levels and regulating TIMPs levels[3].

**The Role of Inflammation on Obesity**

Inflammatory processes play a pivotal role in obesity. PGs play a role in inflammation. COXs play a role in converting the arachidonic acid into PGs. Some of PGs: PGE<sub>2</sub>, PGF<sub>2α</sub>, PGD<sub>2</sub> and PGJ<sub>2</sub> has been reported to induce obesity by different ways, either by inducing adipogenesis or inhibiting lipolysis[3,46,47]. PGE<sub>2</sub> work as enhancer to lipid accumulation in hepatocytes and participated in the development of hepatic steatosis[3-50]. PGF<sub>2α</sub> is a potent inhibitor of adipocyte differentiation[3,48,49]. COX-2 play a role in activation of PGE<sub>2</sub>[3-51], so increase the COX-2 levels will increase the activation rate of PGE<sub>2</sub> which will lead to obesity and vice versa. Interestingly, there is an inverse relationship

between PGs levels and fat mass. Moreover, vitamin D may play a role in modulating the inflammatory process in obese subjects, 1,25(OH)<sub>2</sub>D<sub>3</sub> and its analogs has been reported that it has a role in down regulating PGs synthesis by inhibiting selectively the activity of COX-2[3,52,53].

### Vitamin D Status in Middle East

Vitamin D deficiency and its comorbid conditions are a pandemic health problem, especially in the Middle East, in particular in Saudi Arabia because of limited outdoor activities and the prevalence of wearing dark skin covering clothes for cultural and religious reasons[13-14]. As a matter of fact, 30-50% of children and adults in UAE, Australia, Turkey, India and Lebanon have been found to have vitamin D deficiency[13,75,76]. Although, Saudi Arabia is one of the sunniest countries, vitamin D deficiency has long been reported as prevalent in Saudi population[15,77,78]. A study done by Ardawiet *al.* reported an approximately 80% prevalence of vitamin D deficiency in 1172 Saudi women from the western region of Saudi Arabia[15-79].

### Dosing Considerations of Vitamin D

Nowadays, new studies proved that the optimum dose of vitamin D<sub>3</sub> supplements is depend on body weight [4,65,66], so we suggest that obese subjects have to receive two to three times vitamin D more than non-obese to satisfy their body's vitamin D requirements[4-64].

However, if the target of vitamin D supplementation in obese was to affect one of comorbidities associated with obesity, the dose will be various for each comorbid condition [4].

## CONCLUSIONS

The function of adipose tissues is not only as nutritive storage[5]. Recently, it classified as a major endocrine organ. Vitamin D is a fat soluble prohormone. It is easily stored and sequestered in adipose tissue. Also, it can be stored in muscles. The deficiency of vitamin D is common in obese subjects. Many efforts have been made in the understanding of vitamin D metabolism and functions. Interestingly, several studies provided the interrelationship between vitamin D and adipose tissue, it may both regulate and be regulated by vitamin D[6]. It is able to act via numerous genomic and non-genomic mechanisms: including protein expression, inflammation, and cellular metabolism. There is a clear relationship between FTO rs9939609 and being obese in childhood in Brazilian Amazon. Moreover, some evidence proved an association between genetic effects of FTO and vitamin D levels. Likewise, it has been proved a relationship between pediatric obesity, adiponectin and vitamin D levels. The decrease in vitamin D levels will lead to decrease in circulating adiponectin and as a result there will be an increase in the total body weight. In fact, vitamin D deficiency and its comorbid conditions are a pandemic health problem, particularly in Saudi Arabia in the western region due to their food lifestyle, limited outdoor activities and the prevalence of wearing dark skin covering clothes for cultural and religious reasons.

## ABBREVIATIONS

PTH, Parathyroid hormone; cAMP, Urinary cyclic adenosine 3,5-monophosphate; 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1 $\alpha$ , 25-hydroxyvitamin D<sub>3</sub>; 25(OH)D, 25-hydroxyvitamin D<sub>3</sub>; IL, Interleukin; VDR, Vitamin D receptor; UV-B, Ultraviolet B; BMI, Body mass index; MMPs, Matrix metalloproteinases; TIMP-1, Tissue inhibitor of metalloproteinase-1; VDR-KO, Vitamin D receptor-knock-out; PGs, Prostaglandins; COX, Cyclooxygenase; LMW, Low molecular weight; MMW, Medium molecular weight; HMW, High molecular weight; CNS, Central nervous system.

**REFERENCES**

1. Shin Y, Shin H and Lee Y. Vitamin D status and childhood health. *Korean J Pediatr.* 2013. 56(10):417-423.
2. Walker G, Ricotti R, Roccio M, Moia S, Bellone S, Prodam F and Bona G. Pediatric obesity and vitamin D deficiency: a proteomic approach identifies multimeric adiponectin as a key link between these conditions. *PLOS ONE.* 2014. 9(1).
3. Khanhvinhquốc Lương and Lan Thi Hoàng Nguyễn. The beneficial role of vitamin D in obesity: possible genetic and cell signaling mechanisms. *Nutrition Journal.* 2013. 89(12).
4. Cipriani C, Pepe J, Piemonte S, Colangelo L, Cilli M and Minisola S. Vitamin D and its relationship with obesity and muscle. *International Journal of Endocrinology.* 2014.
5. Mutt S, Hyppönen E, Saarnio J, Järvelin M and Herzig K. Vitamin D and adipose tissue - more than storage. *Frontiers in physiology.* 2014.
6. Earthman CP, Beckman LM, Masodkar K and Sibley SD. The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. *International Journal of Obesity.* 2012. 36:387–396.
7. Ghergherehchi R and Tabrizi A. Vitamin D deficiency and secondary hyperparathyroidism in pediatric obesity. *Casp J Intern Med.* 2010. 4(1):119-127.
8. Lourenço B, Qi L, Willett W and Cardoso M. FTO Genotype, Vitamin D status and weight gain during childhood. *Diabetes.* 2014. 63(2):808-814.
9. Wikipedia. Matrix metalloproteinase. 2014. [http://en.wikipedia.org/wiki/Matrix\\_metalloproteinase](http://en.wikipedia.org/wiki/Matrix_metalloproteinase) (Accessed 2014-10-9).
10. 2012. Adipose tissue. <http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/A/AdiposeTissue.html> (Accessed 2014-10-9).
11. Wikipedia. Lean body mass. 2014. [http://en.wikipedia.org/wiki/Lean\\_body\\_mass](http://en.wikipedia.org/wiki/Lean_body_mass) (Accessed 2014-10-12).
12. Crozier SR, Harvey NC, Inskip HM, Godfrey KM, Cooper C and Robinson SM. Maternal vitamin D status in pregnancy is associated with adiposity in the offspring: findings from the Southampton Women's Survey. *The American Journal of Clinical Nutrition.* 2012. 96(1):57-63.
13. Al-Othman A, Al-Musharaf S, Al-Daghri N, Krishnaswamy S, Yusuf D, Alkharfy K, Al-Saleh Y, Al-Attas O, Alokail M, Moharram O, Sabico S and Chrousos G. Effect of physical activity and sun exposure on vitamin D status of Saudi children and adolescents. *BMC Pediatrics.* 2012. 92(12):1471-2431.
14. Torun E, Gönüllü E, Özgen E, Cindemir E and Öktem F. Vitamin D deficiency and insufficiency in obese children and adolescents and its relationship with Insulin resistance. *International Journal of Endocrinology.* 2013.
15. Al-Elq A. The status of vitamin D in medical students in the preclerkship years of Saudi medical school. *Journal of Family and Community Medicine.* 2012. 19(2):100-104.
16. Holick MF. Vitamin D deficiency. *N Engl J Med.* 2007. 357:266-81.

17. Verstuyf A, Carmeliet G, Bouillon R and Mathieu C. Vitamin D: a pleiotropic hormone. *Kidney Int.* 2010. 78:140-5.
18. Temmerman JC. Vitamin D and cardiovascular disease. *J Am Coll Nutr.* 2011. 30:167-70.
19. Shin YH, Kim KE, Lee C, Shin HJ, Kang MS, Lee HR, et al. High prevalence of vitamin D insufficiency or deficiency in young adolescents in Korea. *Eur J Pediatr.* 2012. 171:1475-80.
20. Camargo CA Jr, Ingham T, Wickens K, Thadhani R, Silvers KM, Epton MJ, et al. Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. *Pediatrics.* 2011. 127: e180-7.
21. Ford ES, Zhao G, Tsai J and Li C. Vitamin D and all-cause mortality among adults in USA: findings from the National Health and Nutrition Examination Survey Linked Mortality Study. *Int J Epidemiol.* 2011. 40:998-1005.
22. Reis JP, von Muhlen D, Miller ER 3rd, Michos ED and Appel LJ. Vitamin D status and cardiometabolic risk factors in the United States adolescent population. *Pediatrics.* 2009. 124: e371-379.
23. Zhou P, Schechter C, Cai Z and Markowitz M. Determinants of 25(OH)D sufficiency in obese minority children: selecting outcome measures and analytic approaches. *J Pediatr.* 2011. 158: 930-934.e1.
24. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. *J Biol Chem.* 2003. 278: 9073-9085.
25. Shetty S, Kusminski CM and Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. *Trends Pharmacol Sci.* 2009. 30: 234-239.
26. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, et al. Adiponectin acts in the brain to decrease body weight. *Nat Med.* 2004. 10: 524-529.
27. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. *Nat Med.* 2005. 11:1096-1103.
28. Sun X and Zemel MB. Calcium and 1,25-dihydroxyvitamin D3 regulation of adipokine expression. *Obesity (Silver Spring).* 2007. 15: 340-348.
29. Scherer PE, Williams S, Fogliano M, Baldini G and Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. *J Biol Chem.* 1995. 270(45): 26746-26749.
30. Tamer G, Mesci B, Tamer I, Kilic D and Arik S. Is vitamin D deficiency an independent risk factor for obesity and abdominal obesity in women? *Endokrynol Pol.* 2012. 63:196-201.
31. Saliba W, Barnett-Griness O and Rennert G. The relationship between obesity and the increase in serum 25(OH)D levels in response to vitamin D supplementation. *Osteoporos Int.* 2012. Epub ahead of print.
32. Lee SH, Kim SM, Park HS, Choi KM, Cho GJ, et al. Serum 25 hydroxyvitamin D levels, obesity and the metabolic syndrome among Korean children. *Nutr Metab Cardiovasc Dis.* 2012. Epub ahead of print.
33. Miksztowicz V, Siseles N, Machulsky NF, Schreier L and Berg G. Increase in MMP-2 activity in overweight and obese women is associated with menopausal status. *Climacteric.* 2012. 15:602-606.



34. Laimer M, Kaser S, Kranebitte M, Sandhofer A, Muhlmann G, et al. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. *Int J Obes*. 2005. 29:498-501.
35. Garvin P, Nilsson L, Carstensen J, Jonasson L and Kristenson M. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. *PLoS One*. 2008. 3:e1774.
36. Głowińska-Olszewska B and Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. *Metabolism*. 2007. 56:799-805.
37. Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, et al. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. *Clin Biochem*. 2009. 42:984-990.
38. Morgan AR, Han DY, Thompson JM, Mitchell EA and Ferguson LR. Analysis of MMP2 promoter polymorphisms in childhood obesity. *BMC Res Notes*. 2011. 4:253.
39. Andrade VL, Fernandes KS, Bosco AA, Tanus-Santos JE and Sandrim VC. Functional polymorphism located in MMP-9 gene promoter is strongly associated with obesity. *DNA Cell Biol*. 2012. 31:1054-1057.
40. Belo VA, Souza-Costa DC, Luizon MR, Lanna CM, Carneiro PC, et al. Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children. *Int J Obes (Lond)*. 2012. 36:69-75.
41. Sundar I, Hwang J, Wu S, Sun J and Rahman I. Deletion of vitamin D receptor leads to premature emphysema/COPD by increased matrix metalloproteinase and lymphoid aggregates formation. *Biochem Biophys Res Commun*. 2011. 406:127-133.
42. Timms P, Mannan N and Hitman G. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? *Q J Med*. 2002. 95:787-796.
43. Bahar-shany K, Ravid A and Koren R. Upregulation of MMP-production by TNF $\alpha$  in keratinocytes and its attenuation by vitamin D. *J Cell Physiol*. 2010. 222:729-737.
44. Lacraz S, Dayer J, Nicod L and Welgus H. 1,25-dihydroxyvitamin D<sub>3</sub> dissociates production of interstitial collagenase and 92-kDa gelatinase in human mononuclear phagocytes. *J Biol Chem*. 1994. 269:6485-6490.
45. de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. *Proc Natl Acad Sci U S A*. 1997. 94:7303-7307.
46. Fujitani Y, Aritake K, Kanaoka Y, Goto T, Takahashi N, et al. Pronounced adipogenesis and increased insulin sensitivity caused by overproduction of prostaglandin D<sub>2</sub> in vivo. *FEBS J*. 2010. 277:1410-1419.
47. Ghoshal S, Trivedi DB, Graf GA and Loftin CD. Cyclooxygenase-2 deficiency attenuates adipose tissue differentiation and inflammation in mice. *J Biol Chem*. 2011. 286:889-898.
48. Casimir DA, Miller CW and Ntambi JM. Preadipocyte differentiation blocked by prostaglandin stimulation of prostanoid FP<sub>2</sub> receptor in murine 3T3-L1 cells. *Differentiation*. 1996. 60:203-210.
49. Fujimori K, Ueno T and Amano F. Prostaglandin F<sub>2</sub> $\alpha$  suppresses early phase of adipogenesis, but is not

- associated with osteoblastogenesis in mouse mesenchymal stem cells. *Prostaglandins Other Lipid Mediat.* 2010. 93:52-59.
50. Henkel J, Frede K, Schanze N, Vogel H, Schürmann A, et al. Stimulation of fat accumulation in hepatocytes by PGE2-dependent repression of hepatic lipolysis,  $\beta$ -oxidation and VLDL-synthesis. *Lab Invest.* 2012. 92:1597-1606.
  51. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. *Cancer Discov.* 2012. 2:356-365.
  52. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM and Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. *Cancer Research.* 2005. 65:7917-7925.
  53. Aparna R, Subhashini J, Roy KR, Reddy GS, Robinson M, et al. Selective inhibition of cyclooxygenase-2 (COX-2) by 1  $\alpha$ ,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog. *J Cell Biochem.* 2008.104:1832-1842.
  54. K. S. Vimalaswaran, D. J. Berry, C. Lu et al. Causal relationship between obesity and vitamin D status: bidirectional Mendelian randomization analysis of multiple cohorts. *PloS Medicine.* 2013. 10(2), Article ID e1001383.
  55. J. Wortsman, L. Y. Matsuoka, T. C. Chen, Z. Lu, and M and F. Holick. Decreased bioavailability of vitamin D in obesity. *American Journal Clinical Nutrition.* 2000. 72(3):690-693.
  56. E. B. Mawer, J. Backhouse, C. A. Holman, G. A. Lumb, and S. W. Stanbury. The distribution and storage of vitamin D and its metabolites in human tissues. *Clinical Science.* 1972. 43(3):413-431.
  57. H. Florez, R. Martinez, W. Chacra, N. Strickman-Stein, and S. Levis. Outdoor exercise reduces the risk of hypovitaminosis D in the obese. *Journal of Steroid Biochemistry and Molecular Biology.* 2007. 103(3-5):679-681.
  58. G. Targher, L. Bertolini, L. Scala et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. *Nutrition, Metabolism and Cardiovascular Diseases.* 2007. 17(7):517-524.
  59. C. Ding, V. Parameswaran, L. Blizzard, J. Burgess, and G. Jones. Not a simple fat-soluble vitamin: changes in serum 25-(OH)D levels are predicted by adiposity and adipocytokines in older adults. *Journal of Internal Medicine.* 2010. 268(5):501-510.
  60. T. Romacho, M. Elsen, D. Röhrenborn, and J. Eckel. Adipose tissue and its role in organ crosstalk. *Acta Physiologica.* 2014. 210(4):733-753.
  61. B. Gustafson, A. Hammarstedt, S. Hedjazifar, and U. Smith. Restricted adipogenesis in hypertrophic obesity: the role of WISP2, WNT, and BMP4. *Diabetes.* 2013. 62(9):2997-3004.
  62. M. Sneve, Y. Figenschau, and R. Jorde. Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. *European Journal of Endocrinology.* 2008. 159(6):675-684.

63. S. A. Shapses, E. J. Lee, D. Sukumar, R. Durazo-Arvizu, and S. H. Schneider. The effect of obesity on the relationship between serum parathyroid hormone and 25-hydroxyvitamin D in women. *Journal of Clinical Endocrinology and Metabolism*. 2013. 98(5):886-890.
64. M. F. Holick, N. C. Binkley, H. A. Bischoff-Ferrari et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism*. 2011. 96(7):1911-1930.
65. E. Romagnoli, J. Pepe, S. Piemonte, C. Cipriani, and S. Minisola. Management of endocrine disease: value and limitations of assessing vitamin D nutritional status and advised levels of vitamin D supplementation. *European Journal of Endocrinology*. 2013. 169(4):59-69.
66. E. Grethen, R. McClintock, C. E. Gupta et al. Vitamin D and hyperparathyroidism in obesity. *Journal of Clinical Endocrinology and Metabolism*. 2011. 96(5):1320-1326.
67. Cecil JE, Tavendale R, Watt P, Hetherington MM and Palmer CNA. An obesity-associated FTO gene variant and increased energy intake in children. *N Engl J Med*. 2008. 359:2558-2566.
68. Sovio U, Mook-Kanamori DO, Warrington NM, et al. Early Growth Genetics Consortium. Association between common variation at the FTO locus and changes in body mass index from infancy to late childhood: the complex nature of genetic association through growth and development. *PLoS Genet*. 2011. 7:e1001307.
69. Eriksson JG. Early growth and coronary heart disease and type 2 diabetes: findings from the Helsinki Birth Cohort Study (HBCS). *Am J Clin Nutr*. 2011. 94(Suppl.):1799S-1802S.
70. Tschritter O, Preissl H, Yokoyama Y, Machicao F, Häring HU and Fritsche A. Variation in the FTO gene locus is associated with cerebrocortical insulin resistance in humans. *Diabetologia*. 2007. 50:2602-2603.
71. Brüning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. *Science*. 2000. 289:2122-2125.
72. Kelly A, Brooks LJ, Dougherty S, Carlow DC and Zemel BS. A cross-sectional study of vitamin D and insulin resistance in children. *Arch Dis Child*. 2011. 96:447-452.
73. Belenchia AM, Tosh AK, Hillman LS and Peterson CA. Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: a randomized controlled trial. *Am J Clin Nutr*. 2013. 97:774-781.
74. Ye WZ, Reis AF, Dubois-Laforgue D, Bellanne-Chantelot C, Timsit J and Velho G. Vitamin D receptor gene polymorphisms are associated with obesity in type 2 diabetic subjects with early age of onset. *Eur J Endocrinol*. 2001. 145:181-186.
75. El-Hajj Fuleihan G, Nabulsi M, Choucair M, Salamoun M, Hajj Shahine C, Kizirian A and Tannous R. Hypovitaminosis D in healthy school children. *Pediatrics*. 2001. 107(53).
76. Sedrani SH. Low 25-Hydroxy vitamin D and normal serum calcium concentrations in Saudi Arabia: Riyadh region. *Ann Nutr Metab*. 1984. 28:181-185.
77. Sedrani SH, Elidrissy AW and El Arabi KM. Sunlight and vitamin D status in normal Saudi subjects. *Am J Clin Nutr*. 1983. 38:129-32.

78. Fonseca V, Tongia R and El-Hazmi M. Exposure to sunlight and vitamin D deficiency in Saudi Arabian women. *Postgrad Med J.* 1984. 6-:589-91.
79. Ardawi MS, Qari MH, Rouzi AA, Maimani AA and Raddadi RM. Vitamin D status in relation to obesity, bone mineral density, bone turnover markers and vitamin D receptor genotype in healthy Saudi pre- and postmenopausal women. *Osteoporos Int.* 2011. 22:463-75.
80. Reinehr T, De Sousa G, Alexy U, Kersting M and Andler W. Vitamin D status and parathyroid hormone in obese children before and after weight loss. *Eur J Endocrinol.* 2007. 157:225-32.
81. Stretched skin. <http://img1.wikia.nocookie.net/cb20140412033804/creepypasta/images/f/fc/Layers-of-Skin-shutterstock.jpg> (Accessed 2014-11-8).
82. Classroomclipart. 2011. [http://classroomclipart.com/clipart-view/Clipart/Anatomy/10-12-10-S\\_14A\\_jpg.htm](http://classroomclipart.com/clipart-view/Clipart/Anatomy/10-12-10-S_14A_jpg.htm) (Accessed 2014-11-8).
83. Biochemistry university of Wisconsin-Madison. 9/8/2014. <http://www.biochem.wisc.edu/medialab/clipart/liver.gif> (Accessed 2014-11-8).
84. Molecules - medical health care concept - vitamin supplements. [http://www.123rf.com/photo\\_30421821\\_stock-vector-molecules--medical-health-care-concept--vitamin-supplements.html](http://www.123rf.com/photo_30421821_stock-vector-molecules--medical-health-care-concept--vitamin-supplements.html) (Accessed 2014-11-8).
85. Clipartpanda. Fish, Meat, and Eggs Clipart. <https://translate.google.com.sa/?hl=en&tab=wT#en/ar/Fish%2C%20Meat%2C%20and%20Eggs%20-%20Clipart>. (Accessed 2014-11-8).
86. Hasbro and Lauren Faust. 2011. <http://spaceponies.deviantart.com/art/Sun-in-the-Book-239893883> (Accessed 2014-11-8).